Success Metrics

Clinical Success Rate
80.6%

Based on 75 completed trials

Completion Rate
81%(75/93)
Active Trials
20(15%)
Results Posted
91%(68 trials)
Terminated
18(14%)

Phase Distribution

Ph phase_2
44
34%
Ph not_applicable
14
11%
Ph early_phase_1
2
2%
Ph phase_3
17
13%
Ph phase_1
37
28%
Ph phase_4
15
12%

Phase Distribution

39

Early Stage

44

Mid Stage

32

Late Stage

Phase Distribution129 total trials
Early Phase 1First-in-human
2(1.6%)
Phase 1Safety & dosage
37(28.7%)
Phase 2Efficacy & side effects
44(34.1%)
Phase 3Large-scale testing
17(13.2%)
Phase 4Post-market surveillance
15(11.6%)
N/ANon-phased studies
14(10.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.3%

75 of 97 finished

Non-Completion Rate

22.7%

22 ended early

Currently Active

20

trials recruiting

Total Trials

130

all time

Status Distribution
Active(25)
Completed(75)
Terminated(22)
Other(8)

Detailed Status

Completed75
Terminated18
Active, not recruiting11
Recruiting9
unknown7
Not yet recruiting5

Development Timeline

Analytics

Development Status

Total Trials
130
Active
20
Success Rate
80.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.6%)
Phase 137 (28.7%)
Phase 244 (34.1%)
Phase 317 (13.2%)
Phase 415 (11.6%)
N/A14 (10.9%)

Trials by Status

terminated1814%
not_yet_recruiting54%
active_not_recruiting118%
completed7558%
withdrawn43%
suspended11%
unknown75%
recruiting97%

Recent Activity

Clinical Trials (130)

Showing 20 of 130 trialsScroll for more
NCT07570173Phase 2

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Not Yet Recruiting
NCT06043323Phase 2

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting
NCT07542730Phase 4

Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions

Not Yet Recruiting
NCT05285813Phase 2

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Active Not Recruiting
NCT00961792Not Applicable

Chicago Social Drinking Project

Active Not Recruiting
NCT05501678Phase 2

Trial of Diphenhydramine for Sleep in Children With Autism

Recruiting
NCT04268498Phase 2

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active Not Recruiting
NCT07472413Phase 3

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Not Yet Recruiting
NCT05896228Phase 2

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT04862221Phase 2

TReatment for ImmUne Mediated PathopHysiology

Recruiting
NCT06356571Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
NCT04224558Phase 1

Stem Cell Transplantation in Crohn's Disease

Recruiting
NCT04432597Phase 1

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Active Not Recruiting
NCT03913559Phase 2

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Terminated
NCT04221477Phase 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Active Not Recruiting
NCT04918147Phase 2

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
NCT04681105Phase 1

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Completed
NCT07358689Phase 2

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Not Yet Recruiting
NCT06083571Phase 2

Intranasal Ketorolac Trial

Terminated
NCT06207305Phase 1

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
130